摘要
目的 探讨甲状腺乳头状微小癌(PTMC)BRAF^(V600E)基因突变分析及其与临床病理特征的关系。方法 收集2019-01—2021-07中国医科大学附属盛京医院434例PTMC患者手术切除组织,采用ARMS法检测BRAF^(V600E)基因突变情况。结果 434例PTMC患者中BRAF^(V600E)基因突变的突变率为85.0%(369/434)。肿瘤直径≥0.5 cm且≤1 cm的患者BRAF^(V600E)基因突变率明显高于肿瘤直径<0.5 cm的患者,差异有统计学意义(P=0.002)。在男性或年龄<45岁分组中,有淋巴结转移的患者BRAF^(V600E)基因突变率均明显高于无淋巴结转移患者,差异有统计学意义(P=0.001=0.028)。结论 在男性或年龄<45岁的PTMC患者中,BRAF^(V600E)基因突变与淋巴结转移具有相关性,为临床对患者预后评估提供一定的参考价值。
Objective To perform a mutation analysis of BRAFV600 Ein patients with papillary thyroid microcarcinoma(PTMC) and to explore its relationship with clinicopathological characteristics. Methods From January 2019 to July 2021, 434 patients with PTMC undergoing surgical resection were selected from Shengjing Hospital, China Medical University. The BRAFV600 Emutation was detected using the Amplification Refractory Mutation System method. Results The BRAFV600 Emutation rate in 434 patients with PTMC was 85.0%(369/434). The mutation rate in patients with a tumour diameter ≥0.5 cm but ≤ 1 cm was significantly higher than that in patients with a tumour diameter <0.5 cm(P=0.002). In the male and < 45 years of age groups, the BRAFV600 Emutation rate in patients with lymph node metastasis was significantly higher than that in patients without lymph node metastasis(P=0.001 and P=0.028, respectively). Conclusion In male PTMC patients and the patients < 45 years of age, the BRAFV600 Emutation is related to lymph node metastasis. This provides a theoretical basis for using this mutation for the clinical evaluation of patient prognosis.
作者
张莹
刘姝颖
王哲
ZHANG Ying;LIU Shu-ying;WANG Zhe(Department of Pathology,Shengjing Hospital of China Medical University,Shenyang 110004,China)
出处
《诊断病理学杂志》
2022年第11期1028-1031,共4页
Chinese Journal of Diagnostic Pathology
作者简介
通讯作者:王哲。E-mail:wangz@sj-hospital.org。
